Sabby Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Sabby Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-380	Closed	-$110K	–	192
2017 Q3	$110K	Sell	380 -1,323	-78%	-$361K	0.01%	142
2017 Q2	$436K	Sell	1,703 -2,070	-55%	-$556K	0.03%	149
2017 Q1	$1.25M	Buy	3,773 +882	+31%	+$409K	0.07%	121
2016 Q4	$1.74M	Buy	+2,891	New	+$3.05M	0.1%	114
2015 Q3	–	Sell	-225	Closed	-$226K	–	413
2015 Q2	$226K	Sell	225 -263	-54%	-$284K	0.01%	296
2015 Q1	$496K	Buy	488 +363	+290%	+$1.2M	0.02%	236
2014 Q4	$417	Sell	125 -73	-37%	-$224K	0.01%	195
2014 Q3	$575	Sell	198 -49	-20%	-$162K	0.02%	176
2014 Q2	$940K	Buy	+247	New	+$930K	0.04%	157

Other funds holding NBSE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Sabby Management's NBSE Position: Q4 2017 in Review

Sabby Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2017, closing a stake of 380 shares — an estimated $110K sold.

Sabby Management first reported a position in NBSE in Q2 2014 and held it in 9 quarters. The position peaked at $1.74M in Q4 2016. 40 funds tracked by Wall St. Rank hold NBSE as of Q4 2017.

Sabby Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
Sabby Management sold 380 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $110K.
Sabby Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 9 quarters.
Sabby Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $1.74M in Q4 2016.
40 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.